Viatris VTRS Product and Service, Other — Other revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viatris in its filing.
Tagged under the XBRL concept us-gaap:RevenueNotFromContractWithCustomer.
The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viatris's product and service, other — other revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viatris's product and service, other — other revenues?
- Viatris (VTRS) reported product and service, other — other revenues of $7.3M in Q1 2026.
- How has Viatris's product and service, other — other revenues changed year-over-year?
- Viatris's product and service, other — other revenues decreased by 34.2% year-over-year, from $11.1M to $7.3M.
- What is the long-term trend for Viatris's product and service, other — other revenues?
- Over 2 years (2021 to 2023), Viatris's product and service, other — other revenues has grown at a -27.2% compound annual growth rate (CAGR), from $72.7M to $38.5M.
- What does product and service, other — other revenues mean?
- This metric represents revenue streams generated by a business segment that fall outside of its primary core product or service offerings. It typically includes ancillary income, such as contract manufacturing services, licensing fees, or secondary service agreements that support the broader pharmaceutical portfolio. Tracking these revenues helps investors understand the diversification of the company's income base beyond its main generic and branded drug sales.